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Background. Few data are available on the stereoselective pharmacokinetics of tramadol in
children. The aim of this study was to develop a population pharmacokinetic model for
the (+)- and (2)-enantiomers of tramadol and its O-demethyl tramadol metabolite (M1) in
children.
Methods. Twenty-five children (1–8 yr) were included in this study. Tramadol was adminis-
tered after surgery by continuous infusion (loading dose, 2 mg kg21 i.v. over 10 min followed
by continuous infusion of 8 mg kg21 over 24 h). If pain relief was inadequate, additional 1 mg
kg21 i.v. bolus doses of tramadol were given over 10 min. A two-compartment structural
model was used with NONMEM.
Results. For both enantiomers of tramadol, weight was the only patient characteristic par-
ameter showing significant covariate effects on clearance (CL). CL increased by 5.7–6.1 litre
h21 between 8–12 and 13–16 kg, and by 2.4–3.3 litre h21 between 13–16 and 17–33 kg.
The rate constants associated with the metabolite elimination [0.144 h21, (+)-M1 and 0.18
h21, (2)-M1] were smaller than the elimination rate constants of the parent drugs [0.243 h21,
(+)-tramadol and 0.241 h21, (2)-tramadol], suggesting that the metabolite disposition was
rate-limited by its elimination. The presence of two subpopulations of patients was suspected
on the basis of the observed bimodal distributions of the AUCM1/AUCtramadol ratios.
Conclusions. The results of this study combine relationships between tramadol CL and
patient covariates that may be useful for dose adjustment. Polymorphism is likely to contribute
to the interpatient variability observed in the AUC M1/AUC tramadol ratios.
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Keywords: analgesia, paediatric; population stereoselective pharmacokinetics; tramadol;
O-demethyl tramadol
Accepted for publication: December 5, 2008
Tramadol is a synthetic 4-phenyl-piperidine analogue of
codeine containing two chiral centres. This drug is mar-
keted as a racemic mixture of the (+)- and (2)-enantiomers
and is classified as a phase IIb analgesic according to the
WHO pain score. Tramadol is a centrally acting analgesic
and has been recommended recently to relieve mild to
moderate postoperative pain in children. Two complemen-
tary mechanisms are defined for its mode of action. The
opioid activity of tramadol is the result of moderate
affinity binding of the (+)-enantiomer to m-receptor. In
addition, the (+)-enantiomer inhibits serotonin reuptake
and the (2)-enantiomer is a more effective inhibitor of
norepinephrine reuptake.1 2
Tramadol is rapidly absorbed after oral administration
with an absolute bioavailability of 65–70% due to a first-
pass metabolism after absorption from the gastrointestinal
tract.1 3 It is rapidly and extensively metabolized in the
liver resulting in many phase I and II metabolites.
The main metabolic pathways, O- and N-demethylation,
involve cytochrome P-450 iso-enzymes 2D6, 2B6, and
3A4, respectively. Of all the metabolites, the primary
O-demethyl tramadol (M1) metabolite is the only pharma-
cologically active metabolite3 with a greater affinity for
the m-receptor than the parent drug.2 4 The stereoselective
pharmacokinetics of tramadol has been described in adults
after enteral and parenteral administration.5–9
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Maturation of metabolic pathways must be kept in mind
to allow relevant prescription in children. Metabolic clear-
ance (CL) of drugs is usually very low at birth, then
increases to reach a maximum at about 1 yr of age when it
can exceed that of adults. However, it has been demon-
strated that metabolic CL of tramadol is almost complete by
44 weeks post-conceptional age.10 Simultaneously, water
compartments are significantly larger in children than in
adults. Thus, treatment of postoperative pain by drugs exten-
sively metabolized in the liver remains difficult. Although
tramadol seems a very promising drug in paediatric pain
treatment, few pharmacokinetic data are available.10–15
They have been described after i.v. infusion,10–12 15 caudal
epidural,10 oral drop,14 or rectal13 administration. Both
non-compartmental and compartmental (using one- or two-
compartment model) approaches have been used. A popu-
lation pharmacokinetic/pharmacodynamic modelling of the
analgesic effects of tramadol has recently been developed
by Garrido and colleagues.12 In all these studies, non-
stereoselective pharmacokinetic analyses were performed.
More recently, Di Patti and colleagues16 proposed a
mathematical model for the kinetics of tramadol to adjust
the administered dose, depending on the genetic poly-
morphisms of CYP2D6.
The present study was carried out to provide data on
pharmacokinetics of both enantiomers of tramadol and its
active metabolite (M1) in a homogenous paediatric popu-
lation aged 1–8 yr old. The purpose of this study was (i)
to determine accurate population pharmacokinetic par-
ameters of the (+)- and (2)-enantiomers of tramadol and
its M1 metabolite by using a two-compartment open
model, (ii) to accurately estimate both inter- and
intra-individual variability in pharmacokinetic parameters,
and (iii) to examine which of the patient physio-
pathological parameters could have influenced drug
disposition.
Methods
A total of 25 consecutive ASA I–III children, age range
1–8 yr, undergoing laparoscopic fundoplication for gastro-
oesophageal reflux at Lapeyronie Hospital (Montpellier,
France) were enrolled. Pre-anaesthetic data and results
from physical examination and standard laboratory tests
including haematological and biochemical tests were
recorded before the study. Children with renal dysfunction
(creatininaemia .1 mg dl21), or hepatic dysfunction
(direct bilirubinaemia .2 mg dl21), were excluded from
the study. Also those receiving analgesics or anti-
inflammatory drugs the week before surgery were
excluded.
One hour before surgery, children were given midazo-
lam (0.4 mg kg21) as rectal premedication. On arrival in
the operating theatre, i.v. cannulation was performed and
anaesthesia was started with propofol (4 mg kg21) and
remifentanil (1 mg kg21). After tracheal intubation,
anaesthesia was maintained with sevoflurane (1 MAC
end-tidal concentration in 50% oxygen) and remifentanil
(0.4 mg kg21 min21). Neuromuscular block was obtained
with atracurium (0.5 mg kg21 to obtain and maintain a
train-of-four count of 1) at the beginning of surgery. A
second i.v. cannula was inserted into the femoral vein to
facilitate subsequent blood sampling. After surgery, chil-
dren received niflumic acid, a selective inhibitor of
cyclooxygenase-2, by rectal route (20 mg kg21 twice a
day), acetaminophen i.v. (30 mg kg21, four times a day),
and tramadol hydrochloride i.v. according to the following
protocol: the loading dose, 2 mg kg21 over 10 min was
given at wound closure followed by continuous infusion of
8 mg kg21 over 24 h. In addition, 1 mg kg21 bolus doses
were infused in 10 min if pain relief was not adequate, but
no more than twice within 1 h, and no more than five
times for the 24 h study period. If pain remained unaccep-
table, tramadol would be stopped and rescue analgesia
would be provided using i.v. morphine. Pain, evaluated
every hour and 30 min after each additional dose of trama-
dol, was considered unacceptable when the Children and
Infants Postoperative Pain Score (CHIPPS)17 exceeded 2
on a maximum of 10 (Table 1).
The study protocol was reviewed and approved by the
Institutional Review Board. The study was performed in
accordance with the legal requirements and the Declara-
tion of Helsinki, and with current European Community
and US Food and Drug Administration guidelines for good
clinical practice. Written consent was obtained from the
parents (or legal guardians).
Blood samples (2.5 ml) were obtained at the following
times: (i) immediately before and (ii) at the end of the
loading dose, (iii) 12 and 24 h after the beginning of infu-
sion, and (iv) 0.25, 0.5, 1, 2, 4, 6, and 12 h after the end
of infusion. Immediately after collection, samples were
centrifuged (1500g) at 48C for 10 min, then plasma
samples were immediately frozen (2308C) until assay.
Table 1 Children and infants postoperative pain scale. In the postoperative
period, 4 points or more indicate an analgesic demand with increasing
urgency17
Item Structure Points
Crying None 0
Moaning 1
Screaming 2
Facial expression Relaxed/smiling 0
Wry mouth 1
Grimace (mouth and eyes) 2
Posture of the trunk Neutral 0
Variable 1
Rear up 2
Posture of the legs Neutral, released 0
Kicking about 1
Tightened legs 2
Motor restlessness None 0
Moderate 1
Restless 2
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Enantiomers of tramadol and O-demethyl tramadol were
quantified in human plasma by high-performance liquid
chromatography (HPLC) using tandem-mass spectrometry
detection. The detection and quantification were carried
out in the multiple reaction monitoring mode using ethyl
tramadol as an internal standard. The chromatographic
separation was performed on a reversed-phase Chiralpack
HPLC column (2504.6 mm, particle size 10 mm) operat-
ing at room temperature (218C), with a Lichrospher 100
diol pre-column (44 mm). The mobile phase was a
mixture of n-hexane/ethanol/diethylamine (94:6:0.1, v/v/v).
The flow rate was set to 1.0 ml min21. Samples were
extracted using the solid phase extraction (SPE) automate
Aspec XL4 on C2 (50 mg, encapped) cartridges. SPE car-
tridges were first conditioned with 1 ml of methanol and
1 ml of distilled water and then plasma samples were
loaded onto the cartridges. The column was then rinsed
twice with 1 ml of distilled water. The elution was carried
out with 2 0.5 ml of methanol. The organic phase was
evaporated under a stream of nitrogen at 408C. For all
compounds, the assays were linear in the range of 0.50–
100 mg litre21. From the analysis of quality control
samples (three levels) against calibration curves, the pre-
cision was ,11% and the accuracy was 97–103%. The
lower limit of quantification for all compounds was 0.50
mg litre21, being the lowest concentrations of the standard
curves with a precision of 4.0–8.9% and accuracy of
96.8–109%. Dilutions (1:20 and 1:200) did not alter the
performances of the method. Extraction efficiency ranged
between 90.5% and 102% for the four analyses.
The following patient characteristic data were available
for each patient: age, weight, gender, height, and body
surface area (BSA). Strong correlations were found
between BSA and weight (r=0.99) and between age and
height (r=0.93). Thus, the following potential explanatory
patient’s covariates, weight, age and gender, were included
in the original data files.
Pharmacostatistical model (base model)
The pharmacokinetic analysis was performed using
the non-linear mixed-effect modelling approach as
implemented in the NONMEM computer program
(version 5.1)18 through the Visual-NM graphical inter-
face.19 For the parent drugs, first-order conditional
estimation was used to fit the models because individual
data sets were extensive.18 For the metabolites, as few
concentration–time data were collected during the for-
mation phase, the formation rate constant proved to be dif-
ficult to estimate; the estimation was markedly improved
with first-order estimation. The population characteristics
of the pharmacokinetic parameters (fixed and random
effects) were estimated using the subroutines ADVAN-1,
ADVAN-2, ADVAN-4, or ADVAN-5 from the library of
programs provided with the NONMEM-PREDPP package.
The compartmental analysis was performed by treating the
parent drug and its metabolites separately. The following
structural models were investigated: (i) for the parent
drugs: one-, two-, and three-compartment models with
zero-order input; and (ii) for the metabolites: one- and
two-compartment models with first-order formation of the
O-demethyl tramadol, with or without a lag time. The
structural model was chosen on the basis of changes in 22
log likelihood and on graphical analyses of the
goodness-of-fit. Because 22 log likelihood is approxi-
mately x2 distributed and the addition of one compartment
increases the degrees of freedom by a factor of two, a
change of 5.99 in 22 log likelihood was required at the
5% significance level to select the more complex model.
Deviations of each parameter of the jth individual from
the estimated population average values were modelled
with the use of an exponential interindividual variability
error model:
Pj ¼ Pmean  expðhjÞ ð1Þ
where Pj is the required pharmacokinetic parameter in the
jth individual and hj a random variable distributed with
mean zero and variance of v2h about the average value
(Pmean) in the population.
Various error models were also tested (additive, expo-
nential, or combined additive and exponential). The smal-
lest 22 log likelihood function value was associated with
the better model. The error on the concentration measure-
ments of the individual j was best described by an expo-
nential model for (+)-tramadol, (2)-tramadol, and the
(2)-M1 metabolite and a combined additive and exponen-
tial model for the (+)-M1 metabolite given below:
CijðtÞ ¼ f ðPj;Dj; tijÞ  expð1ijÞ ð2Þ
CijðtÞ ¼ f ðPj;Dj; tijÞ  expð11ijÞ þ 12ij ð3Þ
where Pj refers to the parameter vector of the subject j; tij
is the time of the ith measurement; Dj the dosing history of
the subject j; f the pharmacokinetic model; 11ij and 12ij rep-
resent the residual departure of the model from the obser-
vations and contain contributions from intra-individual
variability, assay error, and model misspecification for the
dependent variable. 11 and 12 are assumed to be random
Gaussian variables with mean zero and variances of s211
and s212. The uncertainty (coefficient of variation) in esti-
mating fixed parameter values was determined by expres-
sing the standard error of estimation (calculated in
NONMEM) as a percentage of the estimated value.
Because the fraction of the tramadol dose metabolized
to O-demethyl tramadol (fm) was unknown in this patient
population, the volume of distribution and the total CL
divided by fm were estimated.
In the first step, the population parameters, fixed and
random effects together with the individual posterior esti-
mates, were computed assuming that no dependency
existed between the pharmacokinetic parameters and the
covariates.
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The individual predicted plasma concentrations
(IPREDs) were calculated for each individual by means of
the empirical Bayes estimate of pharmacokinetic par-
ameters using the POSTHOC option in the NONMEM
program.
Covariate inclusion
After selection of the basic structural and statistical
models, a preliminary assessment of covariate influence
was conducted by plotting individual Bayesian pharmaco-
kinetic estimates against all the preselected potential co-
variates. On the basis of these results, models were built
with use of a stepwise forward addition process followed
by a backward elimination process. When a significant
relationship was observed, the selected covariates were
included individually in the model and tested for statistical
significance. The change in the NONMEM objective func-
tion produced by the inclusion of a covariate term (asymp-
totically distributed as x2 with degrees of freedom equal to
the number of parameters added to the model) was used to
compare alternative models. A change in objective func-
tion of at least 3.8 (P,0.05 with one degree of freedom)
was required for statistical significance at the initial covari-
ate screening stage. Finally accepted covariates were
added to the model and the population pharmacokinetic
parameters were estimated. To demonstrate that retained
covariates contributed to an improvement of the fit of the
population pharmacokinetic model, each covariate was
deleted sequentially from the proposed final model (back-
ward elimination) in order to confirm statistical signifi-
cance (x2 test). If the objective function did not vary
significantly, the relationship between the covariate and
the pharmacokinetic parameter was ignored.
Final model
Only the covariates providing a significant change in the
objective function when introduced in the model were
retained in the analysis. The final population parameters
were estimated considering the relationship with the
covariates.
At each step of the model building, diagnostic plots
were analysed for closeness to and randomness along the
line of identity on observed concentrations (DV) vs pre-
dicted (PRED) concentration plot, and randomness along
the residual (DV-PRED) and weighted residual zero line
on the predicted concentrations or time vs residual or
weighted residual plot. Moreover, IPREDs were plotted vs
DV, and the results were compared with the reference line
of slope=1 and intercept=0. PRED concentrations were
computed based on population parameter estimates;
IPRED concentrations were computed based on individual
parameter estimates. Descriptive statistics were used to
compare mean residual values to 0 and to calculate 95%
confidence intervals. The model was accepted when:
(i) plots showed no systematic pattern and (ii) descriptive
statistics did not show any systematic deviation from the
initial hypothesis (mean supposed to be 0).
Results
Of the 25 patients enrolled in this study, one patient was
removed due to an error in the preparation of the drug to
be infused (excessive dilution). Characteristics of the chil-
dren are presented in Table 2. Patients had no other
medical history besides their gastro-oesophageal reflux.
Eighteen patients received additional doses of tramadol,
17 of these within the first 90 min after the beginning of
infusion. Six patients received two to four additional
doses. A mean of 11 mg kg21 day21 was given to achieve
adequate pain relief. A maximum of 14 mg kg21 day 21
was administered to one child. No child required morphine
rescue analgesia.
Median pain was scored 0 and ranged from 0 to 4 on
the CHIPPS scale. No sedation was recorded.
Twenty-eight per cent of patients experienced nausea at
least once during the postoperative course; however, all of
them were able to drink and eat at the end of the study
period. No otherwise clinically significant adverse effects
were recorded during the study. Overall parents’ satisfac-
tion was recorded 3 (range 2–3) on a scale extending
from 0 to 3.
Pharmacokinetics of (+)-tramadol and (2)-tramadol
At the end of infusion, mean (SD) plasma concentrations
were 189 (77.1) mg litre21 for (+)-tramadol and 170 (69.3)
mg litre21 for (2)-tramadol. Disposition of tramadol in
plasma was best characterized by a two-compartment open
model. This model significantly improved the objective
function compared with the one- or the three-compartment
model (Table 3). The four-dimensional vector u of kinetic
parameters considered in the population analysis consists
of CL, initial volume of distribution (V1), and transfer rate
constants (k12 and k21). From the individual (Bayesian esti-
mates) primary pharmacokinetic parameters: the volume
of distribution at steady state (Vdss) and the elimination
half-life (t1/2 elim) were calculated. The goodness-of-fit was
evaluated (i) by comparing the regression line estimated
on the IPRED vs observed concentrations [(+)-tramadol:
slope=0.97 (SE=0.019), intercept=0.18 mg litre21 (SE=4.04)
and (2)-tramadol: slope=0.98 (SE=0.018), intercept=2.07
Table 2 Patient characteristics
Age (yr) Weight (kg) Height (cm) Body surface
area (m2)
Mean 3.76 15.8 98.6 0.66
95% CI 2.93–4.55 13.6–18.1 92.4–104.9 0.59–0.72
Minimum 1.17 8.9 68.5 0.41
Maximum 8.17 33 131.5 1.1
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mg litre21 (SE=3.45)] to the reference line of slope=1 and
intercept=0; no significant difference occurred, and (ii) by
comparing the bias [(+)-tramadol: –4.65 mg litre21, 95%
CI 29.68, 0.38 and (2)-tramadol: 23.13 mg litre21, 95%
CI 27.43, 1.19] with zero; Student’s t-test showed that
these values were not statistically different from zero. In
the model building phase, a significant relationship was
found between CL and weight [P=0.011 for (+)-tramadol
and P=0.0042 for (2)-tramadol] and CL and age
[P=0.043 for (+)-tramadol and P=0.020 for (2)-tramadol].
No covariate significantly explained the variability in V1.
Each covariate was then included individually in the
model; each of them significantly improved the fit of the
basic model (Table 3). At this stage, weight appeared to
be the most important of these factors. In the last step,
these two patient covariates were combined in a full
regression model for CL. In the final model, only weight
was retained. The parameter estimates given by this model
are summarized in Table 4.
Consideration of the relationship between CL and
weight during modelling also improved (i) the relationship
between model-predicted and observed concentrations and
(ii) the plot between weighted residuals and model-
predicted concentrations, and reduced interindividual
variability [(+)-tramadol, from 47.4% to 34.2% and
(2)-tramadol, from 39.6% to 30.8%] and residual error
when compared with the baseline model. A plot of model-
predicted vs observed concentrations for the final model
based on population parameter estimates is shown in
Figure 1. A plot of weighted residuals vs PRED is shown
in Figure 2. The vast majority of weighted residuals lay
within 2 units of perfect agreement and were symmetri-
cally distributed around the zero ordinate.
In mean, the total CL of the (+)-enantiomer was 9.5%
lower than that of the (2)-enantiomer. The body exposure
to (+)-tramadol was greater than that to (2)-tramadol. The
half-lives of the terminal part of the curves were similar
for the two enantiomers.
Pharmacokinetics of (+)-M1 and (2)-M1 metabolites
At the end of the 24 h infusion period, plasma concen-
tration of (2)-M1 metabolite was found higher than that
of (+)-M1 metabolite: 32.8 (15.2) vs 26.2 (13.0) mg
litre21. The basic population pharmacokinetic model was
best represented by a two-compartment model with first-
order formation from tramadol (kf ). Compared with the
one-compartment model, the two-compartment model
decreased the objective function by 26 for the
(+)-enantiomer and by 37.6 for the (2)-enantiomer. The
five-dimensional vector u of kinetic parameters considered
in the population analysis consists of CL/fm, V1/fm, k12,
k21, and kf. During the model building step, a weak
relationship was found between V1/fm and weight [(+)-M1,
Table 4 Pharmacokinetic parameters of tramadol and O-demethyl tramadol.
*CL=aweight+b=13.3 litre h21 (CV, 36.8%); †CL=aweight+b=14.7 litre
h21 (CV, 36.6%); ‡exponential error model; }combined additive and
exponential model. IIV, interindividual variability; IAV, intraindividual
variability; CL, total clearance; V1, initial volume of distribution; k12 and k21,
transfer rate constants; fm, fraction of the tramadol dose metabolized to
O-demethyl tramadol; kf, formation rate constant; Vdss, steady-state volume of
distribution; t1/2, half-life of the terminal part of the curve; DV, observed
concentrations; IPRED, individual predicted concentrations. Values in
parentheses are the error of estimate expressed as coefficient of variation.
Values in brackets are the 95% confidence interval
Mean IIV
(%)
Mean IIV
(%)
(+)-Tramadol (2)-Tramadol
Population parameters
V1 (litre) 25.3 (7.19%) 43.1 34.0 (12.2%) 29.9
CL (litre h21) a=0.407*
(31.0%)
34.2 a=0.617†
(27.2%)
30.8
b=6.19*
(33.8%)
— b=3.94†
(29.9%)
—
k12 (h
21) 0.952 (37.6%) 89.6 0.496 (26.8%) 67.5
k21 (h
21) 1.28 (24.3%) 5.27 0.919 (26.1%) 1.5
IAV (%) 22.0‡ 21.0‡
Bias (DV vs IPRED)
(mg litre21)
23.24 [28.1; 1.63] 22.12 [26.55; 2.30]
Derived parameters
t1/2 (h) 2.85 23.3 2.88 19.9
Vdss (litre) 55.9 41.4 59.8 37.5
(+)-O-demethyl
tramadol
(2)-O-demethyl
tramadol
Population parameters
V1/fm (litre) 331 (43.5%) 40.5 250 (3.35%) 19.3
CL/fm (litre h
21) 108 (14.1%) 48.9 78.2 (11.4%) 44.5
k12 (h
21) 0.224 (37.2%) 85.5 0.668 (27.9%) 121
k21 (h
21) 0.501 (33.5%) 114 1.10 (31.1%) 11.1
kf (h
21) 1.93 (67.0) 93 2.86 (48.2%) 125
IAV (%) 22.2‡ 19.3%; 1.99 mg litre21}
Bias (DV vs IPRED)
(mg litre21)
20.283 [20.83; 0.26] 20.12 [20.78; 0.54]
Derived parameters
t1/2 (h) 4.78 37.6 3.86 30.0
Vdss/fm (litre) 753 66.3 455 44.7
Table 3 Model building steps. D, difference in the objective function
Models Number of
parameters
Objective function
(+)-Tramadol (2)-Tramadol
Model 1: one-compartment
model
2 1892 2004
Model 2: two-compartment
model
4 1834 1816
Model 3:
three-compartment model
6 2188 2168
Model 4: two-compartment
model including a
relationship between CL
and weight
(CL=aweight+b)
5 1816 (D=18) 1772 (D=44)
Model 5: two-compartment
model including a
relationship between CL
and age (CL=aage+b)
5 1830 (D=4) 1800 (D=16)
Model 6: two-compartment
model including weight
and age
6 1816 (D=18) 1772 (D=44)
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P=0.0462 and (2)-M1, P=0.0137]. When added to the
model, weight did not significantly decrease the objective
function. No covariates significantly explained the varia-
bility in CL/fm. The parameter estimates given by this
model are summarized in Table 4.
Predicted and observed plasma concentration–time pro-
files for (+)-tramadol and (+)-M1 in a child are presented in
Figure 3. The terminal disposition phases [(+)-M1, half-life:
4.78 h and (2)-M1, half-life: 3.86 h] were delayed compared
with the elimination of tramadol (2.85 and 2.88 h, respect-
ively), suggesting that the metabolite disposition may involve
an elimination rate-limitation process. Body exposures to the
(+)- and (2)-M1 were 14% and 19%, respectively, that of
the parent compounds; mean AUC ratios (metabolite/parent
drug) were 0.141 (range: 0.059–0.27) and 0.185 (range:
0.095–0.31), respectively. Visual inspection of these ratios
suggests a bimodal distribution (Fig. 4). No relationship
between these ratios and patient’s age was evidenced. Such a
bimodal distribution could be attributed to the difference in
tramadol metabolism between patients.
Discussion
Few data are available on the pharmacokinetics of trama-
dol in children. In most of the previous studies, only the
pharmacokinetic profile of the parent drug was described.
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Fig 1 Model performance and diagnostic plots. Model-predicted vs observed plasma concentrations based on population parameter estimates (the line
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This is the first description of the population pharmacoki-
netics of the (+)- and (2)-enantiomers of tramadol and its
M1 metabolite in children (1–8 yr). For both tramadol
and its M1 metabolite, the two-compartment model pro-
duced the best fit. For the metabolite, most of the data
were collected in the post-metabolism phase and the for-
mation constant (kf ) could not be accurately estimated; for
this reason, high standard errors of estimation were
obtained on this parameter.
Only weight showed significant covariate effects on CL
of both enantiomers of tramadol. The inclusion of this co-
variate in the model substantially reduced interindividual
variability in (+)-tramadol and (2)-tramadol CL (13.2%
and 8.8%, respectively). CL increased by 5.7–6.1 litre h21
between 8–12 and 13–16 kg, and by 2.4–3.3 litre h21
between 13–16 and 17–33 kg. Although a weak relation-
ship was found between weight and the initial volume of
distribution of the metabolites, this relationship was not
retained in the final models. These results were in accord-
ance with those published by Garrido and colleagues.12
However, in the study of Allegaert and colleagues,11 a
model including age-related changes for tramadol CL and
volume of distribution was used. These discrepancies could
be explained by the differences in the characteristics of the
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Fig 2 Model performance and diagnostic plots. Weighted residuals (WRES) vs predicted plasma concentrations. (A) (þ)-Tramadol and (B) (2)-
tramadol.
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patients between the two populations. Indeed, in the study
published by Allegaert and colleagues, 20 neonates and
young infants (0–3 months post-natal age) and 20 adults
were included.
The estimates of tramadol CLs observed in the present
population pharmacokinetic analysis [0.87 litre h21 kg21
for the (+)-enantiomer and 0.95 litre h21 kg21 for the
(2)-enantiomer] were similar to the total CL of the
racemic reported by Garrido and colleagues,12 but higher
than that reported by Murthy and colleagues10 and Payne
and colleagues14 (0.37 litre h21 kg21) (Table 5). In these
last two studies, tramadol was administered before anaes-
thesia, whereas in the study of Garrido and colleagues12
and in our study, tramadol was administered after surgery.
Thus, alteration in hepatic blood flow during surgery,
anaesthesia, or both could have affected some of the phar-
macokinetic data.10 11
The steady-state volumes of distribution of the (+)- and
(2)-enantiomers of tramadol (3.4 and 3.8 litre kg21) were
similar to those reported by others for the racemic
(Table 5) and were higher than the physiological water
volume.
Tramadol is metabolized via the hepatic cytochrome
P450 enzyme system by O-demethylation. In adults, M1
plasma concentration was about 25% that of the tramadol
concentrations.20 21 In our study, plasma concentration of
the (+)-M1 metabolite was 14% (range: 5.9–27%) that of
the parent drug and concentration of the (2)-M1 metab-
olite was 19% (range: 9.5–31%) that of the parent drug.
These results are in accordance with those reported by
Murthy and colleagues10 (AUCM1/AUCtramadol, 20%) and
Payne and colleagues14 (AUCM1/AUCtramadol, 18%). In the
present study, the presence of two subpopulations of
patients was suspected on the basis of the bimodal distri-
bution of the AUCM1/AUCtramadol ratios. Tramadol is
metabolized by the CYP2D6 enzyme which is affected by
a genetic polymorphism in 5–10% of the Caucasian popu-
lation. Phenotyping and genotyping should certainly allow
to clarify the relationship between genetic polymorphism
and pharmacokinetics. However, ethical considerations did
not allow us to investigate this hypothesis. Further studies
are required to confirm these results in a larger population
of children.
Formation of the (+)- and (2)-enantiomers of the M1
metabolite from the parent drug was rapid; 12 h after
the start of infusion, the steady state was already
achieved. The rate constants associated with the metab-
olite elimination [0.144 h21 for the (+)-M1 and 0.18
h21 for the (2)-M1] were smaller than the elimination
rate constants of the parent drugs [0.243 h21 for the
(+)-tramadol and 0.241 h21 for the (2)-tramadol]
suggesting that the metabolite disposition was rate-
limited by its elimination. In this case, half-life of the
metabolite decline represents the true elimination half-
life of the metabolite.
In conclusion, we have performed a population
approach to estimate individual pharmacokinetic par-
ameters of the two enantiomers of tramadol and
O-demethyl tramadol. The results of this study combine
relationships between tramadol CL and patient covariates
that may be useful for dose adjustment. Polymorphism is
likely to contribute to the interpatient variability observed
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in the AUCM1/AUCtramadol ratios. A mean of 11 mg kg
21
day21 was given to achieve adequate pain relief. A
maximum of 14 mg kg21 day21 was administered to one
child. No children required morphine rescue analgesia.
Overall, the treatment was well tolerated by the children
and parents’ satisfaction was good.
Table 5 Main pharmacokinetic parameters in children reported in the literature. N, number of children; T, tramadol; M1, O-demethyl tramadol. *Because the
fraction of the tramadol dose metabolized to M1 (fm) was unknown, the volumes of distribution and the total CL divided by fm were estimated
N Age (yr), mean (min–max) t1/2 elim (h) CL (litre h
21 kg21) V1 (litre kg
21) Vss (litre kg
21) References
14 3.07 (1–12) T 6.4 0.37 — 3.1 Murthy and colleagues10
M1 10.6 — — —
24 5.3 (4–7) T 3.6 0.37 — 4.1 Payne and colleagues14
M1 5.8 — — —
20 0.23 (0–3.2 months) T — 0.48 3.27 3.84 Allegaert and colleagues11
104 4.55 (2–8) T — 0.77 0.40 2.43 Garrido and colleagues12
57 0.2 (0–5 months) T — 0.53 3.1 — Allegaert and colleagues15
24 3.76 (1.17–8.17) T(+) 2.85 0.87 1.72 3.42 Our study
T(2) 2.88 0.95 2.20 3.82
M1(+) 4.78 7.28* 22.6* 49.4*
M1(2) 3.86 5.61* 16.8* 29.7*
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